1453084-37-1

1453084-37-1 structure

Name: Mirvetuximab soravtansine
Chemical Name: Mirvetuximab soravtansine
CAS Number: 1453084-37-1
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Cancer
Create Date: 2023-09-20 21:22:31
Modify Date: 2025-12-09 17:59:43
Mirvetuximab soravtansine (IMGN853) is an antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A. Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage[1].

Name	Mirvetuximab soravtansine

Description	Mirvetuximab soravtansine (IMGN853) is an antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A. Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage[1].
Related Catalog	Research Areas >> Cancer
References	[1]. Ponte JF, et, al. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. Neoplasia. 2016 Dec;18(12):775-784.

No Any Chemical & Physical Properties